{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:55:13Z","timestamp":1793548513779,"version":"4.5.0"},"reference-count":19,"publisher":"Centers for Disease Control MMWR Office","issue":"36","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7336a3","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:09:40Z","timestamp":1726135780000},"page":"793-798","source":"Crossref","is-referenced-by-count":139,"title":["Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024"],"prefix":"10.15585","volume":"73","author":[{"given":"Miwako","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Campos-Outcalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Poehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Loehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R1","unstructured":"CDC. Active Bacterial Core surveillance (ABCs): surveillance reports. Atlanta, GA: U.S Department of Health and Human Services; 2024. https:\/\/www.cdc.gov\/abcs\/reports\/index.html"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023.","volume":"72 (No. RR-3)","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R3","unstructured":"Center for Biologics Evaluation and Research. CAPVAXIVE. Silver Spring, MD: Food and Drug Administration; 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/capvaxive"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R4","unstructured":"Kobayashi M. Evidence to recommendations framework: PCV20 use among adults who previously received PCV13 [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 19, 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/122357"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R5","unstructured":"Orell L, Massay S, Steinberg J,  ISPPD-13: increase in invasive pneumococcal disease due to\n                      Streptococcus pneumoniae\n                      serotype 4\u2014Alaska, 2013\u20132022. Geneva, Switzerland: International Society of Pneumonia and Pneumococcal Diseases; 2024. https:\/\/info.kenes.com\/Flip\/ISPPD24_ISPPD24\/"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R6","unstructured":"Navajo Epidemiology Center. Serotype 4 invasive pneumococcal disease (IPD) information for providers. Window Rock, AZ: Navajo Epidemiology Center; 2024. https:\/\/nec.navajo-nsn.gov\/Portals\/0\/Reports\/ST4%20alert%20for%20NN%20providers_2024.0312.pdf"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jnma.2019.04.011","article-title":"Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the U.S.","volume":"111","author":"Nowalk","year":"2019","journal-title":"J Natl Med Assoc"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40258-023-00854-0","article-title":"Societal cost of racial pneumococcal disease disparities in US adults aged 50 years or older.","volume":"22","author":"Altawalbeh","year":"2024","journal-title":"Appl Health Econ Health Policy"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R9","unstructured":"Accorsi EK, Gierke R, Farley MM,  ISPPD-12: impact of pneumococcal conjugate vaccines on racial differences in invasive pneumococcal disease in black and white persons in the U.S. from 2008 to 2019. Geneva, Switzerland: International Society of Pneumonia and Pneumococcal Diseases; 2022. https:\/\/isppd2022.kenes.com\/abstract-book"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R11","unstructured":"Merck Sharp & Dohme. A study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults (V116-006, stride-6). Rahway, NJ: Merck Sharp & Dohme; 2024. https:\/\/clinicaltrials.gov\/study\/NCT05420961"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R12","unstructured":"Merck Sharp & Dohme. Safety and immunogenicity of V116 in adults living with human immunodeficiency virus (HIV) (V116-007, stride-7). Rahway, NJ: Merck Sharp & Dohme; 2024. https:\/\/clinicaltrials.gov\/study\/NCT05393037"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R13","unstructured":"Platt HL, Bruno C, Buntinx E,  Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial. London, United Kingdom: Lancet Infectious Diseases; 2024. https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(24)00344-X\/fulltext"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R14","unstructured":"Merck Sharp & Dohme. A study to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older (V116-005, STRIDE-5) Rahway, NJ: Merck Sharp & Dohme; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05526716"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R15","unstructured":"Merck Sharp & Dohme. A study to evaluate the safety, tolerability, immunogenicity, and lot consistency of V116 in adults 18 to 49 years of age (V116-004, STRIDE-4). Rahway, NJ: Merck Sharp & Dohme; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05464420"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R16","unstructured":"Leidner AJ. Summary of three economic analyses on the use of 21-valent pneumococcal conjugate vaccine (PCV21) among adults in the United States. [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 26\u201328, 2024 https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2024-06-26-28\/03-Pneumococcal-Leidner-508.pdf"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R17","unstructured":"Stoecker C. Economic assessment of PCV21 in U.S. adults [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 26\u201328, 2024. https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2024-06-26-28.html"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R18","unstructured":"Kroger A, Bahta L, Long S, Sanchez P. Timing and spacing of immunobiologics: general best practice guidelines for immunization. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/timing.html"},{"key":"key-10.15585\/mmwr.mm7336a3-202504010820-R19","unstructured":"Food and Drug Administration. CAPVAXIVE [Package insert]. Silver Spring, MD: US Department of Health and Human Services; 2024. https:\/\/www.fda.gov\/media\/179426\/download?attachment"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:40:56Z","timestamp":1743496856000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/73\/wr\/mm7336a3.htm?s_cid=mm7336a3_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":19,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2024,9,12]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7336a3","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,12]]},"published":{"date-parts":[[2024,9,12]]}}}